These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes. Kuo MT; Savaraj N; Feun LG Oncotarget; 2010 Aug; 1(4):246-51. PubMed ID: 21152246 [TBL] [Abstract][Full Text] [Related]
3. Arginine deprivation by arginine deiminase of Streptococcus pyogenes controls primary glioblastoma growth in vitro and in vivo. Fiedler T; Strauss M; Hering S; Redanz U; William D; Rosche Y; Classen CF; Kreikemeyer B; Linnebacher M; Maletzki C Cancer Biol Ther; 2015; 16(7):1047-55. PubMed ID: 25774632 [TBL] [Abstract][Full Text] [Related]
4. Hypoxia-induced nitric oxide production and tumour perfusion is inhibited by pegylated arginine deiminase (ADI-PEG20). Burrows N; Cane G; Robson M; Gaude E; Howat WJ; Szlosarek PW; Pedley RB; Frezza C; Ashcroft M; Maxwell PH Sci Rep; 2016 Mar; 6():22950. PubMed ID: 26972697 [TBL] [Abstract][Full Text] [Related]
6. Selective Intracellular Delivery of Recombinant Arginine Deiminase (ADI) Using pH-Sensitive Cell Penetrating Peptides To Overcome ADI Resistance in Hypoxic Breast Cancer Cells. Yeh TH; Chen YR; Chen SY; Shen WC; Ann DK; Zaro JL; Shen LJ Mol Pharm; 2016 Jan; 13(1):262-71. PubMed ID: 26642391 [TBL] [Abstract][Full Text] [Related]
7. Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1alpha/Sp4. Tsai WB; Aiba I; Lee SY; Feun L; Savaraj N; Kuo MT Mol Cancer Ther; 2009 Dec; 8(12):3223-33. PubMed ID: 19934275 [TBL] [Abstract][Full Text] [Related]
8. Deciphering molecular mechanisms of arginine deiminase-based therapy - Comparative response analysis in paired human primary and recurrent glioblastomas. Maletzki C; Rosche Y; Riess C; Scholz A; William D; Classen CF; Kreikemeyer B; Linnebacher M; Fiedler T Chem Biol Interact; 2017 Dec; 278():179-188. PubMed ID: 28989041 [TBL] [Abstract][Full Text] [Related]
9. Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1α, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation. Long Y; Tsai WB; Chang JT; Estecio M; Wangpaichitr M; Savaraj N; Feun LG; Chen HH; Kuo MT Oncotarget; 2016 Dec; 7(50):82658-82670. PubMed ID: 27765932 [TBL] [Abstract][Full Text] [Related]
10. Arginine deprivation in cancer therapy. Feun LG; Kuo MT; Savaraj N Curr Opin Clin Nutr Metab Care; 2015 Jan; 18(1):78-82. PubMed ID: 25474015 [TBL] [Abstract][Full Text] [Related]
11. Arginine Deiminase: Current Understanding and Applications. Zarei M; Rahbar MR; Morowvat MH; Nezafat N; Negahdaripour M; Berenjian A; Ghasemi Y Recent Pat Biotechnol; 2019; 13(2):124-136. PubMed ID: 30569861 [TBL] [Abstract][Full Text] [Related]
12. Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction. Long Y; Tsai WB; Wangpaichitr M; Tsukamoto T; Savaraj N; Feun LG; Kuo MT Mol Cancer Ther; 2013 Nov; 12(11):2581-90. PubMed ID: 23979920 [TBL] [Abstract][Full Text] [Related]
13. The role of arginine and the modified arginine deiminase enzyme ADI-PEG 20 in cancer therapy with special emphasis on Phase I/II clinical trials. Synakiewicz A; Stachowicz-Stencel T; Adamkiewicz-Drozynska E Expert Opin Investig Drugs; 2014 Nov; 23(11):1517-29. PubMed ID: 24965808 [TBL] [Abstract][Full Text] [Related]
14. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Ensor CM; Holtsberg FW; Bomalaski JS; Clark MA Cancer Res; 2002 Oct; 62(19):5443-50. PubMed ID: 12359751 [TBL] [Abstract][Full Text] [Related]
15. Arginine Starvation and Docetaxel Induce c-Myc-Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors. Prudner BC; Rathore R; Robinson AM; Godec A; Chang SF; Hawkins WG; Hirbe AC; Van Tine BA Clin Cancer Res; 2019 Aug; 25(16):5122-5134. PubMed ID: 31113844 [TBL] [Abstract][Full Text] [Related]
16. The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma. Thongkum A; Wu C; Li YY; Wangpaichitr M; Navasumrit P; Parnlob V; Sricharunrat T; Bhudhisawasdi V; Ruchirawat M; Savaraj N Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28587170 [TBL] [Abstract][Full Text] [Related]
18. Exploiting Arginine Auxotrophy with Pegylated Arginine Deiminase (ADI-PEG20) to Sensitize Pancreatic Cancer to Radiotherapy via Metabolic Dysregulation. Singh PK; Deorukhkar AA; Venkatesulu BP; Li X; Tailor R; Bomalaski JS; Krishnan S Mol Cancer Ther; 2019 Dec; 18(12):2381-2393. PubMed ID: 31395686 [TBL] [Abstract][Full Text] [Related]
19. Arginine deprivation as a strategy for cancer therapy: An insight into drug design and drug combination. Zhang Y; Chung SF; Tam SY; Leung YC; Guan X Cancer Lett; 2021 Apr; 502():58-70. PubMed ID: 33429005 [TBL] [Abstract][Full Text] [Related]
20. Systems level profiling of arginine starvation reveals MYC and ERK adaptive metabolic reprogramming. Brashears CB; Barlin M; Ehrhardt WR; Rathore R; Schultze M; Tzeng SC; Van Tine BA; Held JM Cell Death Dis; 2020 Aug; 11(8):662. PubMed ID: 32814773 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]